Pharvaris N.V. (FRA:9EN)

Market Cap	1.48B +68.5%
Revenue (ttm)	n/a
Net Income	-163.72M
EPS	-2.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38
Average Volume	13
Open	23.40
Previous Close	23.80
Day's Range	22.80 - 23.60
52-Week Range	10.20 - 25.20
Beta	n/a
RSI	52.26
Earnings Date	Apr 2, 2026

About Pharvaris

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 118
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9EN